Research Papers:

KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models

István Kenessey _, Krisztina Kói, Orsolya Horváth, Mihály Cserepes, Dávid Molnár, Vera Izsák, Judit Dobos, Balázs Hegedűs, József Tóvári and József Tímár

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:79503-79514. https://doi.org/10.18632/oncotarget.12806

Metrics: PDF 903 views  |   HTML 1931 views  |   ?  


István Kenessey1,2, Krisztina Kói1, Orsolya Horváth3, Mihály Cserepes3,4, Dávid Molnár1, Vera Izsák1, Judit Dobos5, Balázs Hegedűs6, József Tóvári3,*, József Tímár1,6,*

12nd Department of Pathology, Semmelweis University, Budapest, Hungary

2National Cancer Registry, National Institute of Oncology, Budapest, Hungary

3Department of Experimental Pharmacology, National Institute of Oncology, Budapest, Hungary

4Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary

5Vichem Chemie Ltd., Budapest, Hungary

6Hungarian Academy of Sciences-Semmelweis University Molecular Oncology Research Group, Budapest, Hungary

*These authors have contributed equally to this work

Correspondence to:

István Kenessey, email: steveken12@yahoo.com

Keywords: zoledronic acid, ras inhibitor, human non-small cell lung cancer, xenograft model

Received: March 17, 2016     Accepted: September 27, 2016     Published: October 21, 2016


Background: In non-small cell lung cancer (NSCLC) KRAS-mutant status is a negative prognostic and predictive factor. Nitrogen-containing bisphosphonates inhibit prenylation of small G-proteins (e.g. Ras, Rac, Rho) and thus may affect proliferation and migration. In our preclinical work, we investigated the effect of an aminobisphosphonate compound (zoledronic acid) on mutant and wild type KRAS-expressing human NSCLC cell lines.

Results: We confirmed that zoledronic acid was unable to inhibit the prenylation of mutant K-Ras unlike in the case of wild type K-Ras. In case of in vitro proliferation, the KRAS-mutant human NSCLC cell lines showed resistance to zoledronic acid wild-type KRAS-cells proved to be sensitive. Combinatory application of zoledronic acid enhanced the cytostatic effect of cisplatin. Zoledronic acid did not induce significant apoptosis. In xenograft model, zoledronic acid significantly reduced the weight of wild type KRAS-EGFR-expressing xenograft tumor by decreasing the proliferative capacity. Futhermore, zoledronic acid induced VEGF expression and improved in vivo tumor vascularization.

Materials and methods: Membrane association of K-Ras was examined by Western-blot. In vitro cell viability, apoptotic cell death and migration were measured in NSCLC lines with different molecular background. The in vivo effect of zoledronic acid was investigated in a SCID mouse subcutaneous xenograft model.

Conclusions: The in vitro and in vivo inhibitory effect of zoledronic acid was based on the blockade of cell cycle in wild type KRAS-expressing human NSCLC cells. The zoledronic acid induced vascularization supported in vivo cytostatic effect. Our preclinical investigation suggests that patients with wild type KRAS-expressing NSCLC could potentially benefit from aminobisphosphonate therapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12806